Chronic excitotoxic lesion of the dorsal raphe nucleus induces sodium appetite.
We determined if the dorsal raphe nucleus (DRN) exerts tonic control of basal and stimulated sodium and water intake. Male Wistar rats weighing 300-350 g were microinjected with phosphate buffer (PB-DRN, N = 11) or 1 microg/0.2 microl, in a single dose, ibotenic acid (IBO-DRN, N = 9 to 10) through a guide cannula into the DRN and were observed for 21 days in order to measure basal sodium appetite and water intake and in the following situations: furosemide-induced sodium depletion (20 mg/kg, sc, 24 h before the experiment) and a low dose of dietary captopril (1 mg/g chow). From the 6th day after ibotenic acid injection IBO-DRN rats showed an increase in sodium appetite (12.0 +/- 2.3 to 22.3 +/- 4.6 ml 0.3 M NaCl intake) whereas PB-DRN did not exceed 2 ml (P < 0.001). Water intake was comparable in both groups. In addition to a higher dipsogenic response, sodium-depleted IBO-DRN animals displayed an increase of 0.3 M NaCl intake compared to PB-DRN (37.4 +/- 3.8 vs 21.6 +/- 3.9 ml 300 min after fluid offer, P < 0.001). Captopril added to chow caused an increase of 0.3 M NaCl intake during the first 2 days (IBO-DRN, 33.8 +/- 4.3 and 32.5 +/- 3.4 ml on day 1 and day 2, respectively, vs 20.2 +/- 2.8 ml on day 0, P < 0.001). These data support the view that DRN, probably via ascending serotonergic system, tonically modulates sodium appetite under basal and sodium depletion conditions and/or after an increase in peripheral or brain angiotensin II.
Cavalcante-Lima
H R
HR
Departamento de Ciências Fisiológicas, Instituto de Biologia, Universidade Federal Rural do Rio de Janeiro, Seropédica, RJ, Brazil.
Badauê-Passos
D
D
de-Lucca
W
W
Lima
H R C
HR
Costa-e-Sousa
R H
RH
Olivares
E L
EL
Cedraz-Mercez
P L
PL
Reis
R O
RO
Medeiros
M A
MA
Côrtes
W S
WS
Reis
L C
LC
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001066:Appetite / Q000187:drug effects* / Q000502:physiology; D002021:Buffers; D002216:Captopril / Q000494:pharmacology; D004326:Drinking / Q000187:drug effects* / Q000502:physiology; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity*; D005665:Furosemide / Q000494:pharmacology; D007051:Ibotenic Acid / Q000633:toxicity*; D008297:Male; D010710:Phosphates; D011903:Raphe Nuclei / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000494:pharmacology; D012982:Sodium, Dietary; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D002021:Buffers; D018690:Excitatory Amino Acid Agonists; D010710:Phosphates; D049994:Sodium Potassium Chloride Symporter Inhibitors; D012982:Sodium, Dietary; D007051:Ibotenic Acid; D005665:Furosemide; D002216:Captopril